N
CTKB icon

Nuveen’s Cytek Biosciences CTKB Stock Holding History

Nuveen’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Sell
245,521
-8,287
-3% -$39.1K ﹤0.01% 2559
2025
Q4 		$1.28M Hold
253,808
– – ﹤0.01% 2492
2025
Q3 		$881K Hold
253,808
– – ﹤0.01% 2681
2025
Q2 		$863K Sell
253,808
-51,177
-17% -$171K ﹤0.01% 2673
2025
Q1 		$1.22M Sell
304,985
-12,316
-4% -$63.8K ﹤0.01% 2549
2024
Q4 		$2.06M Hold
317,301
– – ﹤0.01% 2374
2024
Q3 		$1.76M Hold
317,301
– – ﹤0.01% 2482
2024
Q2 		$1.77M Buy
317,301
+11,636
+4% +$69.9K ﹤0.01% 2444
2024
Q1 		$2.05M Sell
305,665
-12,081
-4% -$95.6K ﹤0.01% 2391
2023
Q4 		$2.9M Buy
317,746
+8,436
+3% +$53.1K ﹤0.01% 2236
2023
Q3 		$1.71M Sell
309,310
-64
-0% -$513 ﹤0.01% 2365
2023
Q2 		$2.64M Sell
309,374
-625,087
-67% -$5.61M ﹤0.01% 2225
2023
Q1 		$8.59M Sell
934,461
-234,421
-20% -$2.52M ﹤0.01% 1577
2022
Q4 		$11.9M Sell
1,168,882
-171,042
-13% -$2.3M ﹤0.01% 1376
2022
Q3 		$19.7M Buy
1,339,924
+895,330
+201% +$11.6M 0.01% 1020
2022
Q2 		$4.77M Buy
444,594
+94,356
+27% +$939K ﹤0.01% 1975
2022
Q1 		$3.98M Buy
350,238
+281,263
+408% +$3.8M ﹤0.01% 2172
2021
Q4 		$1.23M Buy
68,975
+45,889
+199% +$961K ﹤0.01% 2779
2021
Q3 		$494K Buy
+23,086
New +$543K ﹤0.01% 3169

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen's CTKB Position: Q1 2026 in Review

Nuveen reduced its Cytek Biosciences (CTKB) stake by 3.3% in Q1 2026, selling an estimated $39.1K and leaving 245,521 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2559.

Nuveen first reported a position in CTKB in Q3 2021 and has held it in 19 quarters since. The position peaked at $19.7M in Q3 2022. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Nuveen held 245,521 shares of Cytek Biosciences worth $1.07M as of Q1 2026.
  • Nuveen sold 8,287 Cytek Biosciences shares in Q1 2026, an estimated $39.1K.
  • Cytek Biosciences made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2559 holding.
  • Nuveen first reported a position in Cytek Biosciences in Q3 2021 and has held it in 19 quarters since.
  • Nuveen's Cytek Biosciences position peaked at $19.7M in Q3 2022.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.